LP-184 has also shown promise in cancers with DNA damage response deficiencies beyond deficiencies in homologous recombination ... including both solid tumors and blood cancers and an antibody-drug ...
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studiesCollaboration underscores Lonza's commitment to helping customers deliver ...